A Phase 2b Study, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs BPS 804 (Primary)
- Indications Osteogenesis imperfecta
- Focus Therapeutic Use
- Acronyms ASTEROID
- Sponsors Mereo BioPharma
- 08 Aug 2017 According to Mereo BioPharma media release, top-line data from this study is expected in mid-2018.
- 03 May 2017 Status changed from not yet recruiting to recruiting.
- 13 Apr 2017 Status changed from planning to not yet recruiting.